SLC5A2 and heart failure: Recent majorclinical trials with SGLT2 inhibitors, both empagliflozin and dapagliflozin, havenow demonstrated improved cardiovascular outcomes in patients with HFpEF and asignificant reduction in heart failure hospitalization.